Published in Mol Cancer Ther on July 07, 2009
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013) 1.54
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm (2011) 1.06
Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol (2011) 1.01
Regulation and expression of the ATP-binding cassette transporter ABCG2 in human embryonic stem cells. Stem Cells (2012) 0.95
Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood (2013) 0.92
Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase. Mol Cancer (2013) 0.86
Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol (2010) 0.85
LKB1/AMPK and PKA control ABCB11 trafficking and polarization in hepatocytes. PLoS One (2014) 0.85
Temporal changes in innate immune signals in a rat model of alcohol withdrawal in emotional and cardiorespiratory homeostatic nuclei. J Neuroinflammation (2012) 0.84
The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Mol Pharm (2012) 0.78
Complex formation between metabolic enzymes in tumor cells: unfolding the MDR1-IDE paradigm. Mol Cancer Ther (2009) 0.78
Genetic variations in radiation and chemotherapy drug action pathways and survival in locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. PLoS One (2013) 0.76
Influence of TS and ABCB1 gene polymorphisms on survival outcomes of 5‑FU-based chemotherapy in a Chinese population of advanced gastric cancer patients. Wien Klin Wochenschr (2017) 0.75
A gene expression database for the molecular pharmacology of cancer. Nat Genet (2000) 13.31
The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer (2006) 11.49
An information-intensive approach to the molecular pharmacology of cancer. Science (1997) 11.43
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 8.84
Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41
A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A (1998) 6.47
Mammalian ABC transporters in health and disease. Annu Rev Biochem (2001) 4.90
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One (2008) 3.34
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev (2006) 3.22
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull (1996) 2.35
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev (2007) 2.31
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci (2004) 1.87
Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta (2007) 1.79
ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol (2008) 1.65
Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res (2006) 1.64
Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem (1987) 1.40
Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res (2004) 1.32
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol (2004) 1.18
Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract (2008) 1.16
Genomic strategies for personalized cancer therapy. Hum Mol Genet (2007) 1.14
Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther (2007) 1.14
Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol (2005) 1.14
Evidence for the role of glycosylation in accessibility of the extracellular domains of human MRP1 (ABCC1). Biochemistry (2002) 1.12
ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res (2006) 1.11
The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis. Cancer (2003) 1.08
Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray. Mol Pharmacol (2005) 1.05
Gene expression analysis and clinical diagnosis. Clin Chim Acta (2005) 1.04
ABC proteins: key molecules for lipid homeostasis. Med Mol Morphol (2005) 1.02
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science (2006) 15.18
High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). BMC Bioinformatics (2005) 14.02
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
MatchMiner: a tool for batch navigation among gene and gene product identifiers. Genome Biol (2003) 8.66
Nova regulates brain-specific splicing to shape the synapse. Nat Genet (2005) 6.58
Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer (2005) 6.46
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther (2006) 4.09
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res (2008) 3.98
Cell fates as high-dimensional attractor states of a complex gene regulatory network. Phys Rev Lett (2005) 3.90
Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther (2007) 3.84
A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res (2012) 3.74
Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell (2004) 3.72
Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A (2003) 3.66
P-glycoprotein: from genomics to mechanism. Oncogene (2003) 3.66
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res (2003) 3.52
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem (2003) 3.45
Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res (2003) 3.42
Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA (2010) 3.39
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
AffyProbeMiner: a web resource for computing or retrieving accurately redefined Affymetrix probe sets. Bioinformatics (2007) 2.93
Functional mapping - how to map and study the genetic architecture of dynamic complex traits. Nat Rev Genet (2006) 2.87
The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle (2010) 2.84
Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell (2005) 2.82
Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. Science (2011) 2.73
Right vertical infra-axillary mini-incision for repair of simple congenital heart defects: a matched-pair analysis. Eur J Cardiothorac Surg (2012) 2.72
Nitrogen fixation island and rhizosphere competence traits in the genome of root-associated Pseudomonas stutzeri A1501. Proc Natl Acad Sci U S A (2008) 2.70
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol (2009) 2.60
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res (2012) 2.57
Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther (2006) 2.55
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. Cancer Cell (2003) 2.54
DNA fingerprinting of the NCI-60 cell line panel. Mol Cancer Ther (2009) 2.53
MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther (2007) 2.53
Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol (2003) 2.52
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Cleaving the oxidative repair protein Ape1 enhances cell death mediated by granzyme A. Nat Immunol (2003) 2.48
The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol (2007) 2.41
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res (2003) 2.40
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest (2006) 2.28
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res (2013) 2.27
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Cancer Res (2007) 2.26
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Mechanisms of multidrug resistance in cancer. Methods Mol Biol (2010) 2.25
A stromal gene signature associated with inflammatory breast cancer. Int J Cancer (2008) 2.18
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res (2007) 2.15
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem (2005) 2.12
D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol (2011) 2.10
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. Cell Stem Cell (2008) 2.08
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res (2011) 2.08
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 2.07
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res (2008) 2.04
Integrating global gene expression and radiation survival parameters across the 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Cancer Res (2008) 2.01
mRNA and microRNA expression profiles of the NCI-60 integrated with drug activities. Mol Cancer Ther (2010) 2.00
Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2. J Pharmacol Exp Ther (2008) 1.98
Endoscopic thoracic sympathectomy for palmar hyperhidrosis: a randomized control trial comparing T3 and T2-4 ablation. Ann Thorac Surg (2008) 1.97
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res (2004) 1.96
Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res (2007) 1.91
Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med (2010) 1.89
Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst (2010) 1.89
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Replication fork velocities at adjacent replication origins are coordinately modified during DNA replication in human cells. Mol Biol Cell (2007) 1.85